Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients
- 29 July 2005
- journal article
- research article
- Published by Wiley in Pediatrics International
- Vol. 47 (4), 372-377
- https://doi.org/10.1111/j.1442-200x.2005.02101.x
Abstract
Background : Lamivudine treatment in chronic carriers who acquired hepatitis B virus through maternal transmission were investigated. Methods : A total of 29 subjects (Male : Female, 24:5; mean age, 14.7 ± 5.6 years) who were hepatitis B e antigen (HBeAg) seropositive for >6 months, alanine aminotransferase (ALT) was >1.3 times of upper limit of normal value, and receiving a 52 week‐long treatment, received open‐label lamivudine (3 mg/kg per day, maximum 100 mg/day). Another 29 subjects matched for gender, age, liver function, and HBeAg status followed up before the introduction of lamivudine served as the control group. The control group did not receive any treatment and were evaluated at week 52 after the onset of abnormal ALT. Mothers of all study subjects were hepatitis B surface antigen (HBsAg) carriers. A successful treatment response at week 52 was defined as: (i) undetectable hepatitis B virus DNA by real time polymerase chain reaction; (ii) normal ALT; and (iii) HBeAg/anti‐HBe seroconversion. Lamivudine‐resistant YMDD mutants were checked at week 52. Results : The lamivudine group did not reach a better successful treatment response rate than the control group (17 vs 10%, P = 0.44), except in patients with a baseline ALT >5 times of the upper limit of normal value. YMDD mutants developed in 34% of patients in the lamivudine group. Conclusion : Lamivudine treatment is effective for maternally transmitted subjects with high ALT.Keywords
This publication has 23 references indexed in Scilit:
- Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinomaJournal of Hepatology, 2004
- The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infectionThe Journal of Pediatrics, 2004
- Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus InfectionClinical Infectious Diseases, 2003
- Rapid and Specific Genotyping System for Hepatitis B Virus Corresponding to Six Major Genotypes by PCR Using Type-Specific PrimersJournal of Clinical Microbiology, 2001
- Hepatitis B therapy: The plot thickensJournal of Hepatology, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyJournal of Hepatology, 1999
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionThe New England Journal of Medicine, 1995
- The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age*1Journal of Hepatology, 1995
- The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of ageJournal of Hepatology, 1995
- Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in childrenJournal of Hepatology, 1990